This application is filed pursuant to 35 U.S.C. §371 as a United States National Phase Application of International Application No. PCT/EP01/01941 filed 21 Feb. 2001, which claims priority from GB 0004456.0 filed 26 Feb. 2000 in the United Kingdom.
The present invention relates to a medicament dispenser, particularly an inhalation device. The medicament dispenser has a radiofrequency identifier attached thereto.
Medical dispensers are well known for the dispensing of various kinds of medicament. Inhalation devices, such as metered dose inhalers (MDIs) and dry powder inhalers are also well known for the delivery of medicament for the treatment of respiratory disorders.
The manufacture of medical dispensers requires careful control to ensure compliance with product specifications. Similarly, the packaging, distribution and sale of medical dispensers is carefully controlled to ensure consistent product quality and security for the patient. It is common practice to mark the dispenser and any packaging therefor with various codings and serial numbers for use in checking product integrity. Widely used marking techniques include printing and the use of bar codes.
In the event of a patient complaint which results in return of the medical dispenser or indeed in the event of a product recall for any other reason, the manufacturer employs the codings and serial numbers to check the product details.
Counterfeiting is known to be a problem with medical dispensers given the often high resale value of the product. Product marking is further employed to reduce the opportunities for counterfeiting and in particular, to make counterfeit products more readily identifiable.
The Applicants have now devised a method for marking a medical dispenser product of greater sophistication than presently used techniques. The method involves the use of a radiofrequency identifier having a memory structure which allows for large amounts of information to be stored thereon. The memory structure can be arranged such that parts of the memory are read-only, and may be programmed during manufacture, other parts are read/write and further parts are password protectable. Transfer of information to or from the memory is readily achievable by the use of a reader which is typically remote from the medical dispenser, thereby miminising the need for direct product handling. The reader also has the capability of writing information to the memory. In further aspects, the reader can be arranged to simultaneously read the memory of multiple radiofrequency identifiers on multiple medicament dispensers.
A principal advantage of the present invention is the ability to store many types of information in different parts of the memory structure of the radiofrequency identifier on the medical dispenser. The information is furthermore stored in a form which is readily and accurately transferable. The information could for example, include manufacturing and distribution compliance information written to the memory at various points in the manufacturing or distribution process, thereby providing a detailed and readily accessible product history of the dispenser. Such product history information may for example, be referred to in the event of a product recall. The compliance information could for example, include data and time stamps. The information could also include a unique serial number stored in encrypted form or in a password protectable part of the memory which uniquely identifies the product and therefore may assist in the detection and prevention of counterfeiting. The information could also include basic product information such as the nature of the medicament and dosing information, customer information such as the name of the intended customer, and distribution information such as the intended product destination.
PCT patent application no. WO92/17231 describes a metered dose inhaler having a microelectronic assembly thereon. The medicament container includes a set of electrically conducting strips which store information about the medicament container in digital form. The housing of the device includes electrical contact fingers which are contactable with the strips to enable reading of the information to a microelectronic memory on the housing.
According to the present invention there is provided a medicament dispenser comprising a housing; a medicament container; a dispensing mechanism for dispensing medicament from the medicament container; and a radiofrequency identifier, in the form of a radiofrequency identification tag comprising an antenna for transmitting or receiving radiofrequency energy and an integrated circuit chip connecting with the antenna, the radiofrequency identifier connecting to the housing or the medicament container. The dispensing mechanism may, for example, comprise a valve with/without a metering chamber for dispensing aerosol formulations of medicaments, or opening/peeling mechanisms for blister strips/packs for dispensing dry powder medicaments.
The medicament container may for example, be a bottle, vial, drum, syringe, ampoule, blister pack, sachet, cartridge, delivery device, tube, bulk sack, canistor or blister strip. The container may for example, comprise glass, metal, pastic or rubber materials. The medicament may for example, be in powder, liquid, solution, aerosol, or tablet form.
The radiofrequency identifier can be any known radiofrequency identifier. Such identifiers are sometimes known as radiofrequency transponders or radiofrequency identification (RFID) tags or labels. Suitable radiofrequency identifiers include those sold by Phillips Semiconductors of the Netherlands under the trade marks Hitag and Icode, those sold by Amtech Systems Corporation of the United States of America under the trade mark Intellitag, and those sold by Texas Instruments of the United States of America under the trade mark Tagit.
The RFID tags may be used in combination and/or Integrated with other traditional product labelling methods including visual text, machine-readable text, bar codes and dot codes.
Preferably, the antenna is capable of transmitting or receiving radiofrequency energy having a frequency of from 100 KHz to 2.5 GHz.
In one aspect, the antenna is adapted to transmit or receive radiofrequency energy having a frequency of 125 KHz.
In another aspect, the antenna is adapted to transmit or receive radiofrequency energy having a frequency of 13.56 MHz.
In a further aspect, the antenna is adapted to transmit or receive radiofrequency energy having a frequency of 2.4 GHz.
Higher frequencies are preferred because the distance between the reader/writer and the identifier may be increased.
Preferably, the radiofrequency identifier is on a carrier and the carrier is mountable on the housing or the medicament container.
In one aspect, the carrier is a flexible label. In another aspect, the carrier is a rigid disc. In a further aspect, the carrier is a rectangular block. Other shapes of carrier are also envisaged.
Preferably, the carrier is mouldable to the medicament container or housing.
Preferably, the carrier encases the radiofrequency identifier. More preferably, the carrier forms a hermetic seal for the radiofrequency identifier.
In one aspect, the carrier comprises an insulating material such as a glass material or, a paper material or an organic polymeric material such as polypropylene.
Alternatively, the carrier comprises a ferrite material.
Preferably, the integrated circuit chip has a read only memory area.
Preferably, the integrated circuit chip has a write only memory area.
Preferably, the integrated circuit chip has a read/write memory area.
Preferably, the integrated circuit chip has a one-time programmable memory area. More preferably, the one-time programmable memory area contains a unique serial number.
Preferably, the intergrated circuit chip has a preset memory area containing a factory preset, non-changeable, unique data item. The preset memory stem is most preferably in encrypted form.
Preferably, the integrated circuit chip has plural memory areas thereon.
Preferably, any memory area contains data in encrypted form. Electronic methods of checking identity, error detection (e.g. cyclic redundancy check (CRC), and data transfer may also be employed.
Preferably, any memory area is password protected.
In one preferred aspect, the integrated circuit has plural memory areas thereon including a read only memory area containing a unique serial number, which may for example be embedded at the time of manufacture; a read/write memory area which can be made read only once information has been written thereto; and a password protected memory area containing data in encrypted form which data may be of anti-counterfeiting utility.
In one aspect, the medicament container is an aerosol container. Preferably, the aerosol container comprises a suspension of a medicament in a propellant. Preferably, the propellant comprises liquefied HFA134a, HFA-227 or carbon dioxide. Alternatively, the aerosol container comprises a solution of a medicament in a solvent.
In another aspect, the medicament container is a dry-powder container. Preferably, the dry-powder container comprises medicament and optionally excipient in dry-powder form.
Preferably, the medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate, salts or solvates thereof and any mixtures thereof.
Preferably, the housing comprises a mouthpiece for inhalation therethrough.
According to another aspect of the present invention there is provided a system for dispensing medicament comprising a medicament dispenser as hereinbefore described and a reader for reading data from the radiofrequency identifier by transmitting radiofrequency energy thereto and receiving radiofrequency energy therefrom. Preferably the reader is remote from the medicament dispenser and may, for example, be in the form of a hand-held/portable electronic device such as a personal digital assistant (PDA).
Preferably, the reader is capable of reading individual and multiple radiofrequency identifiers simultaneously by differentiating between individual radiofrequency identifiers within the same antenna field. The system thus has ‘anti-collision’ capability.
Preferably the reader is capable of writing data to the radiofrequency identifier by transmitting radiofrequency energy thereto.
Preferably, at least one reader additionally comprises or is in communication with an electronic data management system with input/output capability comprising a memory for storage of data; a microprocessor for performing operations on said data; and a signal output for outputting a signal relating to the data or the outcome of an operation on the data. The electronic data management system may be connected to a local computer or a networked computer system by any suitable method including a hard wired link, an infra red link or any other suitable wireless communications link.
Preferably, the system addtionally comprises a communicator for wireless communication with a gateway to a network computer system to enable transfer of data between the network computer system and the electronic data management system.
Preferably, the communicator enables two-way transfer of data between the network computer system and the electronic data management system.
Preferably, the data are communicable between the network computer system and the electronic data management system in encrypted form. All suitable methods of encryption or partial encryption are envisaged. Password protection may also be employed.
Preferably, the communicator employs radiofrequency or optical signals.
In one aspect, the communicator communicates directly with the gateway.
In another aspect, the communicator communicates with the gateway via a second communications device. Preferably, the second communications device is a telecommunications device, more preferably a cellular phone or pager. Preferably, the communicator communicates with the second communications device using spread spectrum radiofrequency signals. A suitable spread spectrum protocol is the Bluetooth (trade mark) standard which employs rapid (e.g. 1600 times a second) hopping between plural frequencies (e.g. 79 different frequencies). The protocol may further employ multiple sending of data bits (e.g. sending in triplicate) to reduce interference.
In one aspect, the network computer system comprises a public access network computer system. The internet is one suitable example of a public access network computer system, wherein the gateway can be any suitable gateway thereto including gateways managed by an internet service provider. The public access network computer system may also form part of a telecommunications system, which may itself be either a traditional copper wire system, a cellular system or an optical network.
In another aspect, the network computer system comprises a private access network computer system and the gateway is a secure gateway. The private access network system may for example, comprise an intranet or extranet which may for example, be maintained by a health service provider or medicament manufacturer. The secure gateway may for example include password protection; a firewall; and suitable encryption means.
Preferably, the communicator enables communication with a user-specific network address in the network computer system. More preferably, the user-specific network address is selected from the group consisting of a web-site address, an e-mail address and a file transfer protocol address and a data transfer protocol address.
Preferably, the system additionally comprises a data input system for user input of data to the electronic data management system. More preferably, the data input system comprises a man machine interface (MMI) preferably selected from a keypad, voice recognition interface, graphical user interface (GUI) or biometrics interface.
Preferably, the system additionally comprises a display for display of data from the electronic data management system to the user. The display may for example, comprise a screen such as an LED or LCD screen.
According to a further aspect of the present invention there is provided a data communicator for use with a medicament dispenser as hereinbefore described. The data communicator comprises a reader for the radiofrequency identifier capable of reading and writing data therefrom/to by transmitting radiofrequency energy thereto and receiving radiofrequency energy therefrom; and an electronic data management system with input/output capability comprising a memory for storage of said data; a microprocessor for performing operations on the data; and a signal output for outputting a signal relating to the data or the outcome of an operation on the data; and a communicator for communicating with a gateway to a network computer system to enable communication of the data between the network computer system and the microprocessor.
According to a still further aspect of the present invention there is provided a kit of parts comprising a data communicator as hereinbefore described and a medicament dispenser as hereinbefore described. The data communicator may for example, be mechanically coupled to the medicament dispenser by any suitable mechanical mechanism including grip mechanisms and snap-fit mechnisms. In a preferred aspect, the data communicator forms a snap-in module and the dispenser is shaped for receipt of the module.
Embodiments of systems according to the invention will now be described with reference to the accompanying drawings in which:
a is a diagram of a radiofrequency identification (RFID) tag mounted on a rectagular shaped carrier.
b is a diagram of a RFID tag mounted on a disc shaped carrier.
The basic components of an RFID tag are shown in
The first block 402 contains unique tag identifiers such as serial numbers, this information being in a read only format and being encoded on the tag at the time of manufacture such that this information cannot be altered once set.
The second block 403 permits write access conditions to be determined for the third block 404, for example to allow read and write access to the remaining blocks. This block may be considered a ‘secret area’ in that access requires mutual authentication and enciphered data communications are used in this area. The second block 403 may be made read only once information has been written to it, i.e. it may become one time programmable.
The third block 404 can be considered to be a ‘user’ or ‘public’ area in that it may be programmed, by block two 403, such that information may be read from or written to it. This is generally the format in operation, information being read from and written to this area. Access can be password protected and data may be in encrypted format to enhance security.
In use, information from block one 402 (i.e. the unique serial number) will generally be used to identify the tag at each stage in a pre-determined process. Information will also be read from block three 404, to ensure that a given step in the operation has occurred. If satisfied that the operation has taken place successfully then additional information is written to block three 404, following the successful completion of the next stage in the process. Each step in the process is therefore validated and recorded by means of reading data on the chip and by transferring new information to it. These data can be stored electronically and the process monitored from a centralised work station.
The reader 570 reads information from tag 510 to uniquely identify the tag and validate that a particular step in a pre-determined process has occurred. The information may then pass to an electronic data management system 580 with visual display means 585, for processing and storage of the information. This information can be utilised locally or transferred to a networked computer system 590 for further processing and storage. Alternatively, data from the reader 570 may be directly transmitted to the networked computer system 590. Data transfer from the reader 570 to the local electronic data management system 580 and/or to the networked computer system 590 can be mediated by conventional electrical wiring, or by wireless means such as radio or infra red frequency energy. The networked computer system 590 and/or the local electronic data management system 580 may also transmit data to the RFID tag 510 via reader 570 by use of such means, the networked computer 590 communicating directly with reader 570 or indirectly via the data management system 580. The reader 570 then writes information to the RFID tag 510 once a specific process has been completed. User input to the local electronic data management system 580 is by means of a man-machine interface (MMI) in the form of a keyboard 582.
Whilst the present invention has been described in detail in respect of a medicament dispenser actuable manually by the patient it will be appreciated that other actuation mechanisms can be substituted. In particular, the use of a breath operated inhaler in which the actuation is assisted, and is responsive to, preferably triggered by, the inward breath of the patient, is also envisaged.
It may be appreciated that any of the parts of the medicament dispenser of the invention which contact the chemical suspension may be coated with materials such as fluoropolymer materials which reduce the tendency of chemical to adhere thereto. Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP). Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
The medicament dispenser of the invention is in one aspect suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease. Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (e.g. s the sodium salt), ketotifen or nedocromil (e g. as the sodium salt); anti-infectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g. as the acetonide) or 6α, 9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-androsta-1,4-diene-17α-carbothioic acid S-(2-αoxo-tetrahydro-furan3-yl) ester; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g. as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (e.g. as acetate), reproterol (e.g. as hydrochloride), rimiterol, terbutaline (e.g. as sulphate), isoetharine, tulobuterol or 4-hydroxy-7-[2-[[2-[[3-(2-phenylethoxy)propyl]sulfonyl]ethyl]amino]ethyl-2(3H)-benzothiazolone; adenosine 2a agonists, e.g. 2R,3R,4S,5R)-2-[6-Amino -2-(1S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol (e.g. as maleate); α4 integrin inhibitors e.g. (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl]carbonyl}oxy)phenyl]-2-[((2S)-4-methyl-2-{[2-(2-methylphenoxy)acetyl]amino}pentanoyl)amino]propanoic acid (e.g. as free acid or potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (e.g. as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; vaccines, diagnostics and gene therapies. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant. Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) or formoterol (e.g. as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate) or budesonide. A particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).
It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following claims:
Number | Date | Country | Kind |
---|---|---|---|
0004456.0 | Feb 2000 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP01/01941 | 2/21/2001 | WO | 00 | 8/23/2002 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO01/62322 | 8/30/2001 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4679426 | Fuller et al. | Jul 1987 | A |
4724427 | Carroll et al. | Feb 1988 | A |
4817822 | Rand et al. | Apr 1989 | A |
4940966 | Pettigrew et al. | Jul 1990 | A |
5025246 | Schenkel et al. | Jun 1991 | A |
5321619 | Matsuda et al. | Jun 1994 | A |
5347274 | Hassett | Sep 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5368948 | Davies et al. | Nov 1994 | A |
5381137 | Ghaem et al. | Jan 1995 | A |
5448110 | Tuttle et al. | Sep 1995 | A |
5469363 | Saliga et al. | Nov 1995 | A |
5491473 | Gilbert | Feb 1996 | A |
5505195 | Sallis et al. | Apr 1996 | A |
5507277 | Rubsamen et al. | Apr 1996 | A |
5508203 | Fuller et al. | Apr 1996 | A |
5516692 | Berndt | May 1996 | A |
5520166 | Ritson et al. | May 1996 | A |
5528221 | Jeuch et al. | Jun 1996 | A |
5541604 | Meier et al. | Jul 1996 | A |
5549101 | Trofast et al. | Aug 1996 | A |
5560353 | Willemot et al. | Oct 1996 | A |
5582795 | Nishina et al. | Dec 1996 | A |
5583819 | Roesner et al. | Dec 1996 | A |
5587578 | Serra | Dec 1996 | A |
5608739 | Snodgrass et al. | Mar 1997 | A |
5629981 | Nerlikar | May 1997 | A |
5682143 | Brady et al. | Oct 1997 | A |
5706801 | Remes et al. | Jan 1998 | A |
5755218 | Ritson et al. | May 1998 | A |
5770455 | Cargill et al. | Jun 1998 | A |
5771657 | Rice et al. | Jun 1998 | A |
5774875 | Medeiros et al. | Jun 1998 | A |
5777303 | Berney | Jul 1998 | A |
5792668 | Fuller et al. | Aug 1998 | A |
5796602 | Wellan et al. | Aug 1998 | A |
5799651 | Garby et al. | Sep 1998 | A |
5809997 | Wolf | Sep 1998 | A |
5813397 | Goodman et al. | Sep 1998 | A |
5821524 | Horlbeck et al. | Oct 1998 | A |
5844802 | Lepper et al. | Dec 1998 | A |
5874214 | Nova et al. | Feb 1999 | A |
5874896 | Lowe et al. | Feb 1999 | A |
5892441 | Woolley et al. | Apr 1999 | A |
5898370 | Reymond | Apr 1999 | A |
5920054 | Uber, III | Jul 1999 | A |
5955950 | Gallagher et al. | Sep 1999 | A |
5959531 | Gallagher et al. | Sep 1999 | A |
5961925 | Ruediger et al. | Oct 1999 | A |
5963136 | O'Brien | Oct 1999 | A |
5972156 | Brady et al. | Oct 1999 | A |
5981166 | Mandecki et al. | Nov 1999 | A |
5986562 | Nikolich et al. | Nov 1999 | A |
6002344 | Bandy et al. | Dec 1999 | A |
6008727 | Want et al. | Dec 1999 | A |
6017496 | Nova et al. | Jan 2000 | A |
6018299 | Eberhardt et al. | Jan 2000 | A |
6025780 | Bowers et al. | Feb 2000 | A |
6032666 | Davies et al. | Mar 2000 | A |
6040773 | Vega et al. | Mar 2000 | A |
6040774 | Schepps et al. | Mar 2000 | A |
6046003 | Mandecki | Apr 2000 | A |
6049278 | Guthrie et al. | Apr 2000 | A |
6078845 | Friedman et al. | Jun 2000 | A |
6147604 | Hugh et al. | Nov 2000 | A |
6148815 | Wolf | Nov 2000 | A |
6202642 | McKinnon et al. | Mar 2001 | B1 |
6259654 | de la Huerga | Jul 2001 | B1 |
6294999 | Yarin et al. | Sep 2001 | B1 |
6366824 | Nair et al. | Apr 2002 | B1 |
6594611 | Beffa | Jul 2003 | B1 |
6729327 | McFarland | May 2004 | B1 |
6729330 | Scarrott | May 2004 | B1 |
6839604 | Godfrey | Jan 2005 | B1 |
20020198618 | Madden et al. | Dec 2002 | A1 |
20030064029 | Tarara et al. | Apr 2003 | A1 |
20030079744 | Bonney et al. | May 2003 | A1 |
20030183226 | Brand et al. | Oct 2003 | A1 |
20030183697 | Porter | Oct 2003 | A1 |
20040025871 | Davies | Feb 2004 | A1 |
20040100415 | Veitch et al. | May 2004 | A1 |
Number | Date | Country |
---|---|---|
19621179 | Nov 1997 | DE |
19753619 | May 1999 | DE |
19806049 | Aug 1999 | DE |
19826568 | Dec 1999 | DE |
29915334 | Jan 2000 | DE |
645631 | Mar 1995 | EP |
727752 | Aug 1996 | EP |
786357 | Jul 1997 | EP |
831410 | Mar 1998 | EP |
0853288 | Jul 1998 | EP |
859299 | Aug 1998 | EP |
895087 | Feb 1999 | EP |
908840 | Apr 1999 | EP |
947952 | Oct 1999 | EP |
0967568 | Dec 1999 | EP |
2656446 | Jun 1991 | FR |
2760209 | Sep 1998 | FR |
2076259 | Sep 1981 | GB |
2249001 | Apr 1992 | GB |
2262452 | Jun 1993 | GB |
2297225 | Jul 1996 | GB |
2308947 | Jul 1997 | GB |
2312595 | Oct 1997 | GB |
2314418 | Dec 1997 | GB |
2328281 | Feb 1999 | GB |
08195697 | Jul 1996 | JP |
10013295 | Jan 1998 | JP |
10040329 | Feb 1998 | JP |
10049620 | Feb 1998 | JP |
10123147 | May 1998 | JP |
11304812 | Nov 1999 | JP |
11352243 | Dec 1999 | JP |
WO 9212402 | Jul 1992 | WO |
WO 9217231 | Oct 1992 | WO |
WO 9407225 | Mar 1994 | WO |
9522365 | Aug 1995 | WO |
WO 9631790 | Oct 1996 | WO |
WO 9704338 | Feb 1997 | WO |
WO 9707443 | Feb 1997 | WO |
WO 9710896 | Mar 1997 | WO |
WO 9805088 | Feb 1998 | WO |
WO 9815853 | Apr 1998 | WO |
WO 9826312 | Jun 1998 | WO |
WO 9835243 | Aug 1998 | WO |
WO 9846548 | Oct 1998 | WO |
WO 9935091 | Jul 1999 | WO |
WO 9935516 | Jul 1999 | WO |
WO 9948044 | Sep 1999 | WO |
WO 9949408 | Sep 1999 | WO |
WO 9950690 | Oct 1999 | WO |
WO 9965002 | Dec 1999 | WO |
WO 9967099 | Dec 1999 | WO |
WO 9965548 | Dec 1999 | WO |
WO 0003313 | Jan 2000 | WO |
WO 0021031 | Apr 2000 | WO |
WO 0021032 | Apr 2000 | WO |
WP 0021030 | Apr 2000 | WO |
WO 0025720 | May 2000 | WO |
WO 0124690 | Apr 2001 | WO |
WO 0163368 | Aug 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20030011476 A1 | Jan 2003 | US |